Q-omics provides the consensus-scored STK24 profile across patient tissues and cancer cell-line models. STK24 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STK24 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, STK24 RNA expression shows 20,010 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LUAD, and ACC as cancer lineages where STK24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK24 survival associations across molecular data types. STK24 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK24 RNA expression–survival associations across cancer types. High STK24 expression shows unfavorable associations in ACC, LUAD and LUSC, but favorable associations in KIRC, BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STK24 RNA expression.
This table summarizes STK24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STK24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK24 shows higher tumor expression in LUAD, LIHC, BLCA, PAAD, CHOL and LUSC. The LUAD box plot shows higher STK24 RNA expression in tumor versus normal tissue (log2 FC = +0.935, t-test p < 0.001).
This table shows molecular features associated with STK24 in patient tissues and cancer cell lines. In patient samples, STK24 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, STK24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
